News Column

Studies in the Area of Clinical Trials and Studies Reported from Swiss Federal Institute of Technology (From target discovery to clinical trials with...

September 8, 2014



Studies in the Area of Clinical Trials and Studies Reported from Swiss Federal Institute of Technology (From target discovery to clinical trials with armed antibody products)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Clinical Research have been presented. According to news reporting originating from Zurich, Switzerland, by NewsRx correspondents, research stated, "Conventional chemotherapy of serious conditions (e.g., cancer and chronic inflammatory diseases) relies on the use of potent bioactive agents, which do not preferentially localize at the site of disease and which may harm healthy tissues. Intense pharmaceutical research efforts are being devoted to the development of targeted therapeutic agents, capable of selectively homing to diseased tissues, while sparing normal body structures."

Our news editors obtained a quote from the research from the Swiss Federal Institute of Technology, "Biological mass spectrometry and chemical proteomics have revolutionized the way targets for ligand-based pharmacodelivery applications are discovered. In this article, we present a personal account on research activities in the field for the last decade, outlining our experience in the discovery of accessible biomarkers and in the development of potent targeted therapeutic agents. Biological significance The present review discusses evolution of proteomic methodologies applied to the discovery of new targets for therapeutic intervention in cancer and inflammatory diseases."

According to the news editors, the research concluded: "Chemical proteomics-driven target discovery allowed the development of new classes of antibody-based targeting biologics, which are having an impact in the oncological and chronic inflammation clinical research."

For more information on this research see: From target discovery to clinical trials with armed antibody products. Journal of Proteomics, 2014;107():50-55. Journal of Proteomics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Proteomics - www.elsevier.com/wps/product/cws_home/713351)

The news editors report that additional information may be obtained by contacting G. Elia, ETH, Swiss Fed Inst Technol, Dept. of Chem & Appl BioSci, CH-8093 Zurich, Switzerland. Additional authors for this research include T. Fugmann and D. Neri (see also Clinical Research).

Keywords for this news article include: Zurich, Switzerland, Europe, Antibodies, Blood Proteins, Clinical Research, Clinical Trials and Studies, Immunoglobulins, Immunology, Proteomics, Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters